Diabetes Care, Vol 22, Issue 12 1944-1949, Copyright © 1999 by American Diabetes Association

ARTICLES

Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables

M Henricsson, K Berntorp, E Berntorp, P Fernlund and G Sundkvist
Department of Ophthalmology, University Hospital Malmo, Sweden. m.henricsson@angelholm.mail.telia.com

OBJECTIVE: To determine the impact of improved glycemic control on the development and progression of retinopathy after the institution of insulin therapy in patients with type 2 diabetes and to assess the relation to IGF-1 and hemostatic variables. RESEARCH DESIGN AND METHODS: In a prospective observational study, 45 type 2 diabetic patients were examined at baseline and 1, 3, 6, 12, and 24 months after change to insulin therapy. Retinopathy was graded on fundus photographs using the Wisconsin scale; HbA1c, IGF-1, and hemostatic variables were measured. RESULTS: During the observation period of 2 years, 23 patients progressed in the retinopathy scale; 8 progressed > or = 3 levels. After 2 years of insulin treatment, HbA1c and IGF-1 were significantly lower than at baseline, whereas the hemostatic variables had not changed significantly. Progression of retinopathy > or = 3 levels was related to the degree of HbA1c reduction, the duration of diabetes, a higher prothrombin fragment 1 + 2 levels (F1 + 2), but not to other hemostatic variables or IGF-1. The relative risk for progression > or = 3 levels was 2.6 when HbA1c had been reduced > or = 3 percent units (95% CI 1.1-6.1). CONCLUSIONS: The magnitude of improvement of HbA1c by the institution of insulin treatment over a 2-year period may be associated with progression of retinopathy in patients with type 2 diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. B. Brown, K. L. Pedula, and K. H. Summers Diabetic Retinopathy: Contemporary prevalence in a well-controlled population Diabetes Care, September 1, 2003; 26(9): 2637 - 2642. [Abstract] [Full Text] [PDF]

				M. Alvarsson, G. Sundkvist, I. Lager, M. Henricsson, K. Berntorp, E. Fernqvist-Forbes, L. Steen, G. Westermark, P. Westermark, T. Orn, et al. Beneficial Effects of Insulin Versus Sulphonylurea on Insulin Secretion and Metabolic Control in Recently Diagnosed Type 2 Diabetic Patients Diabetes Care, August 1, 2003; 26(8): 2231 - 2237. [Abstract] [Full Text] [PDF]

				M. Henricsson, K. Berntorp, P. Fernlund, and G. Sundkvist Progression of Retinopathy in Insulin-Treated Type 2 Diabetic Patients Diabetes Care, February 1, 2002; 25(2): 381 - 385. [Abstract] [Full Text] [PDF]